Figure 5
Anastrozole cost-effectiveness acceptability curve for postmenopausal women with hormone receptor-positive early breast cancer (25-year data); QALY, quality-adjusted life-year.
Figure 5 | British Journal of Cancer
Anastrozole cost-effectiveness acceptability curve for postmenopausal women with hormone receptor-positive early breast cancer (25-year data); QALY, quality-adjusted life-year.
